Pharmacoeconomic evaluation of fluticasone furoate/umeclidinium/vilanterol powder for inhalation for the treatment of chronic obstructive pulmonary disease
10.12173/j.issn.1005-0698.202404016
- VernacularTitle:氟替美维吸入粉雾剂治疗慢性阻塞性肺疾病的药物经济学评价
- Author:
Xueru DING
1
;
Huimin LIU
;
Xiaodong HE
;
Hua LI
;
Zhihao LI
Author Information
1. 湖北医药学院附属国药东风总医院药学部(湖北十堰 442000)
- Keywords:
Fluticasone furoate/umeclidinium/vilanterol;
Chronic obstructive pulmonary disease;
Markov model;
Cost-utility analysis;
Pharmacoeconomic
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(7):721-730
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the economic value of fluticasone furoate/umeclidinium/vilanterol(FF/UMEC/VI)powder for inhalation in the treatment of symptomatic chronic obstructive pulmonary disease patients with acute exacerbation risk from the perspective of the Chinese health system.Methods Based on subgroup analysis of the China cohort in the IMPACT trial,a four-state lifetime Markov model was established with a 3-month cycle.The model simulation period was 11 years.Clinical efficacy,health benefits,and cost data were obtained through published literature.The health outcomes included quality adjusted life year(QALY).Using 3 times Chinas per capita gross domestic product(GDP)in 2023 as the willingness-to-pay threshold,the cost-utility analysis method was used for analysis the economic viability of FF/UMEC/VI.The scenario analysis,one-way sensitivity analysis and probability sensitivity analysis were used to verify the robustness of the results.Results Compared with fluticasone furoate/vilanterol(FF/VI),FF/UMEC/VI in the treatment of symptomatic chronic obstructive pulmonary disease patients with acute exacerbation risk saved costs 8 118.66 yuan and obtained an additional 0.000 06 QALYs,giving it an economic advantage.Compared with umeclidinium/vilanterol(UMEC/VI),FF/UMEC/VI treatment paid 2 784.41 yuan more and received 0.000 45 QALYs less,making UMEC/VI more cost-utility.The scenario analysis results further confirmed the robustness of the model.The sensitivity analysis results showed that when the drug cost of FF/UMEC/VI per cycle decreases to 637.29 yuan,FF/UMEC/VI had economic benefits under a willingness-to-pay threshold of 3 times China's per capita GDP in 2023.Conclusion For patients with symptomatic chronic obstructive pulmonary disease at risk of acute exacerbation,FF/UMEC/VI is more cost-utility than FF/VI.Compared with UMEC/VI,FF/UMEC/VI has economic viability after price reducing.
